- Home
- DXYZ vs KROS Comparison
DXYZ vs KROS Comparison
Compare DXYZ & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- KROS
- Stock Information
- Founded
- DXYZ N/A
- KROS 2015
- Country
- DXYZ
- KROS United States
- Employees
- DXYZ N/A
- KROS N/A
- Industry
- DXYZ
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- DXYZ
- KROS Health Care
- Exchange
- DXYZ Nasdaq
- KROS Nasdaq
- Market Cap
- DXYZ 640.4M
- KROS 589.8M
- IPO Year
- DXYZ 2024
- KROS 2020
- Fundamental
- Price
- DXYZ $56.33
- KROS $10.86
- Analyst Decision
- DXYZ
- KROS Buy
- Analyst Count
- DXYZ 0
- KROS 11
- Target Price
- DXYZ N/A
- KROS $45.33
- AVG Volume (30 Days)
- DXYZ N/A
- KROS 2.0M
- Earning Date
- DXYZ N/A
- KROS 02-26-2025
- Dividend Yield
- DXYZ N/A
- KROS N/A
- EPS Growth
- DXYZ N/A
- KROS N/A
- EPS
- DXYZ N/A
- KROS N/A
- Revenue
- DXYZ N/A
- KROS $651,000.00
- Revenue This Year
- DXYZ N/A
- KROS $303.39
- Revenue Next Year
- DXYZ N/A
- KROS N/A
- P/E Ratio
- DXYZ N/A
- KROS N/A
- Revenue Growth
- DXYZ N/A
- KROS 8037.50
- 52 Week Low
- DXYZ N/A
- KROS $9.78
- 52 Week High
- DXYZ N/A
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- DXYZ N/A
- KROS 20.25
- Support Level
- DXYZ N/A
- KROS $9.78
- Resistance Level
- DXYZ N/A
- KROS $16.49
- Average True Range (ATR)
- DXYZ 0.00
- KROS 0.92
- MACD
- DXYZ 0.00
- KROS 0.97
- Stochastic Oscillator
- DXYZ 0.00
- KROS 14.52
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.